Absolutions receives FDA breakthrough designation for abdominal wall closure device

The device is designed to reduce the risk of hernia by distributing suture tension over a large area of tissue.

Absolutions Med has received breakthrough designation for an abdominal wall closure device that is intended to reduce the risk of hernia.
The Food and Drug Administration designation, which Absolutions disclosed Wednesday, covers a device designed to distribute suture tension over a large area of tissue.
Absolutions began testing the device, Rebuild Bioabsorbable, in cancer patients undergoing abdominal surgeries in 2022, and the company began a study in a broader population in March 2023.

Sign up for Blog Updates